Skip to main content
Premium Trial:

Request an Annual Quote

Medac Completes Funding to UK Fungal Dx Firm Myconostica

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – UK medical diagnostic firm Myconostica today announced the completion of an investment by German pharmaceutical firm medac Gesellschaft fuer klinishe Spezialpraeparate for an undisclosed amount.

The investment is a continuation of Myconostica's series D round, which had a first close late last year. The funding announced this week will be used to continue development of the company's molecular diagnostic products and to market its existing tests, Myconostica said in a statement.

Based in Manchester, the company specializes in developing tests for life-threatening fungal infections. Earlier this year, Myconostica received a license from Health Canada to sell its Aspergillus molecular diagnostic test in Canada.

Medac is Myconostica's exclusive distributor in Germany. As a result of the investment, Rainer Dickhardt, the managing director of Medac's diagnostics business, will join Myconostica's board.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.